BY THE DIGITAL HEALTH LEADERS FOR THE DIGITAL HEALTH COMMUNITY
BY THE DIGITAL HEALTH LEADERS 
AstraZeneca Completes Acquisition of Fusion Pharma for $2.4 Bn June 7, 2024 This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265.
AstraZeneca Completes Equity Investment with Cellectis May 7, 2024 With this second investment, AstraZeneca now holds a total equity stake of approximately 44% in Cellectis.
AstraZeneca to Acquire Fusion Pharmaceuticals for $2.4 Bn, Strengthens Oncology Porfolio March 21, 2024 This acquisition marks another step in AstraZeneca's ongoing efforts to strengthen its lineup of innovative medicines.
AstraZeneca to Acquire Amolyt Pharma for $1.05 Bn to Boost Rare-Disease Portfolio March 15, 2024 This acquisition of Amolyt backed by EQT Life Sciences is expected to strengthen Alexion, AstraZeneca's rare disease arm.
AstraZeneca to Invest $826.80 Mn in UK to boost Pandemic Preparedness March 8, 2024 To boost UK’s resilience for future pandemics and global health threats, AstraZeneca and the UK Health Security Agency (UKHSA) plan to work in partnership.
AstraZeneca Unveils Drug for HER-2 Positive Breast Cancer Patients in India January 4, 2024 This initiative aims to address the unmet needs of patients with HER-2 positive metastatic breast cancer who have progressed on initial anti-HER2 targeted treatment. It aligns with AstraZeneca's broader objective of leveraging science-driven methods to combat breast cancer.
AstraZeneca to Buy China's Gracell Biotech in a $1.2 Bn Deal December 27, 2023 AstraZeneca will also acquire Gracell's cash, cash equivalents and short-term investments of $234.1 million as of September 30, 2023. The deal is expected to close in the first quarter of 2024.
AstraZeneca Pharma to Launch Breast Cancer Drug December 27, 2023 The cancer drug has received approval from both the European Union and US regulators and is set to be available in India from January 2024. The company has reported promising results from clinical trials, particularly for patients who have previously undergone anti-HER2-based regimens.
AstraZeneca Pharma India Launches COE For Severe Asthma Treatment In Mumbai December 20, 2023 The newly inaugurated CoE is equipped with advanced technologies for asthma management including biologics checklists and data-driven treatment approaches. Further, the center is expected to screen approximately 7,500+ patients within the first 12 months.
AstraZeneca's COPD Treatment Gains Approval from CDSCO December 20, 2023 COPD, the second leading cause of death in India, constitutes over 50% of chronic respiratory diseases and is the third leading cause of death globally.
AstraZeneca Buys Respiratory Vaccine Developer Icosavax in $1.1 Bn Deal December 14, 2023 Icosavax is developing a combination vaccine candidate targeting RSV and human metapneumovirus (hMPV). RSV is a leading cause of pneumonia in toddlers and the elderly, while hMPV causes very similar respiratory tract infections.
AstraZeneca India Partners with Roche Diagnostics to Improve Diagnostic Testing December 13, 2023 The initiative focuses on streamlining HER2 diagnostics with newer advancements in cancer treatment. Further, the partnership will offer comprehensive training initiatives for pathologists and medical oncologists.
